Kadcyla and Spleen enlargement - from FDA reports


Summary

Spleen enlargement is found among people who take Kadcyla, especially for people who are female, 60+ old , have been taking the drug for 1 - 2 years, also take medication Enbrel, and have Breast cancer metastatic. This review analyzes which people have Spleen enlargement with Kadcyla. It is created by eHealthMe based on reports of 1,608 people who have side effects when taking Kadcyla from FDA , and is updated regularly.

What to expect?

If you take Kadcyla and have Spleen enlargement, find out what symptoms you could have in 1 year or longer.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA since 1977. Our tools are simple to use, anonymous and free. Start now >>>

On Nov, 20, 2017

1,608 people reported to have side effects when taking Kadcyla.
Among them, 9 people (0.56%) have Spleen enlargement


Number of reports submitted per year:

Could Kadcyla cause Spleen enlargement?

Time on Kadcyla when people have Spleen enlargement *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 100 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Spleen enlargement when taking Kadcyla *:

  • female: 100 %
  • male: 0.0 %

Age of people who have Spleen enlargement when taking Kadcyla *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 33.33 %
  • 50-59: 33.33 %
  • 60+: 33.33 %

Top conditions involved for these people *:

  • Breast Cancer Metastatic (3 people, 33.33%)
  • Breast Cancer (2 people, 22.22%)
  • Rheumatoid Arthritis (1 person, 11.11%)
  • Metastases To Liver (1 person, 11.11%)
  • Metastases To Bone (1 person, 11.11%)

Top co-used drugs for these people *:

  • Xgeva (1 person, 11.11%)
  • Xeloda (1 person, 11.11%)
  • Rituxan (1 person, 11.11%)
  • Fish Oil (1 person, 11.11%)
  • Enbrel (1 person, 11.11%)

Top other side effects for these people *:

  • Portal Hypertension (3 people, 33.33%)
  • Thrombocytopenia (2 people, 22.22%)
  • Spider Naevus (2 people, 22.22%)
  • Vasculitis (1 person, 11.11%)
  • Bone Disorder (1 person, 11.11%)

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Subscribe to the study: get notified of updates to the study.

Do you have Spleen enlargement when taking Kadcyla?

Expand the study to include all drugs with the same ingredients

Spleen enlargement and drugs with ingredients of ado-trastuzumab emtansine.

Expand the study to include reports from both FDA and eHealthMe

Spleen enlargement and Kadcyla from FDA and eHealthMe reports

Kadcyla

Kadcyla has active ingredients of ado-trastuzumab emtansine. (latest outcomes from Kadcyla 1,612 users)

Spleen enlargement

Spleen enlargement has been reported by people with primary myelofibrosis, rheumatoid arthritis, chronic myeloid leukaemia, hiv infection, high blood pressure (latest reports from 9,022 Spleen enlargement patients).

Browse all side effects of Kadcyla

a b c d e f g h i j k l m n o p q r s t u v w x y z

Drugs that are associated with Spleen enlargement

Spleen enlargement

Could your condition cause Spleen enlargement

Spleen enlargement

Related studies

What would happen?

Forecast new side effects and undetected conditions when you take Kadcyla and have Spleen enlargement.

User reviews to the study

More reviews >